MountainView Hospital was among the first hospitals in the region to offer patients with non-valvular atrial fibrillation (AF) an alternative to long-term warfarin medication with a new left atrial appendage occlusion (LAAO) device. This implant is a first-of-its-kind, proven alternative to long-term warfarin therapy for stroke-risk reduction in patients with non-valvular atrial fibrillation (AF)1.
The LAAO device is intended for percutaneous, transcatheter closure of the left atrial appendage (LAA). Patients with non-valvular atrial fibrillation who are at increased risk for stroke and systemic embolism, are suitable for warfarin and seek a non-pharmacologic alternative to warfarin may be eligible for a LAAO device. By closing off the LAA, a thin, sack-like appendix arising from the left side of the heart that is believed to be the source of a majority of stroke-causing blood clots in people with non-valvular AF, the risk of stroke may be reduced and, over time, patients may be able to stop taking warfarin.
Fulfilling A Need
Non-valvular atrial fibrillation (AF) is an irregular heartbeat that can lead to blood clots, stroke, heart failure and other heart-related complications. AF is the most common cardiac arrhythmia, currently affecting more than five million Americans.2.
- Holmes DR, Seminars in Neurology 2010; 30:528–536
- Colilla et al., Am J Cardiol. 2013; 112:1142-1147